BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release. Mol Pharmacol 2012;82:156-67. [PMID: 22550093 DOI: 10.1124/mol.112.078063] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. Medicine in Drug Discovery 2020;8:100059. [DOI: 10.1016/j.medidd.2020.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ishibashi M, Gumenchuk I, Miyazaki K, Inoue T, Ross WN, Leonard CS. Hypocretin/Orexin Peptides Alter Spike Encoding by Serotonergic Dorsal Raphe Neurons through Two Distinct Mechanisms That Increase the Late Afterhyperpolarization. J Neurosci 2016;36:10097-115. [PMID: 27683906 DOI: 10.1523/JNEUROSCI.0635-16.2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
3 Mlost J, Wąsik A, Starowicz K. Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain. Pharmacol Res 2019;143:40-7. [PMID: 30831242 DOI: 10.1016/j.phrs.2019.02.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
5 Jäntti MH, Mandrika I, Kukkonen JP. Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun 2014;445:486-90. [PMID: 24530395 DOI: 10.1016/j.bbrc.2014.02.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
6 Lee MT, Chiu YT, Chiu YC, Hor CC, Lee HJ, Guerrini R, Calo G, Chiou LC. Neuropeptide S-initiated sequential cascade mediated by OX1, NK1, mGlu5 and CB1 receptors: a pivotal role in stress-induced analgesia. J Biomed Sci 2020;27:7. [PMID: 31915019 DOI: 10.1186/s12929-019-0590-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
8 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
9 Kukkonen JP. Lipid signaling cascades of orexin/hypocretin receptors. Biochimie 2014;96:158-65. [PMID: 23810911 DOI: 10.1016/j.biochi.2013.06.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
10 Lotfi Yagin N, Aliasgharzadeh S, Alizadeh M, Aliasgari F, Mahdavi R. The association of circulating endocannabinoids with appetite regulatory substances in obese women. Obes Res Clin Pract 2020;14:321-5. [PMID: 32580926 DOI: 10.1016/j.orcp.2020.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kukkonen JP. OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells. Cell Signal 2016;28:51-60. [PMID: 26582739 DOI: 10.1016/j.cellsig.2015.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
12 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
14 Palomba L, Motta A, Imperatore R, Piscitelli F, Capasso R, Mastroiacovo F, Battaglia G, Bruno V, Cristino L, Di Marzo V. Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygen-Glucose Deprivation-Induced Neuronal Injury. Cells 2020;9:E1507. [PMID: 32575773 DOI: 10.3390/cells9061507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ahmadi-soleimani SM, Azizi H, Gompf HS, Semnanian S. Role of orexin type-1 receptors in paragiganto-coerulear modulation of opioid withdrawal and tolerance: A site specific focus. Neuropharmacology 2017;126:25-37. [DOI: 10.1016/j.neuropharm.2017.08.024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
16 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
17 Kukkonen JP. G-protein-dependency of orexin/hypocretin receptor signalling in recombinant Chinese hamster ovary cells. Biochem Biophys Res Commun 2016;476:379-85. [PMID: 27237973 DOI: 10.1016/j.bbrc.2016.05.130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Liu M, Min T, Zhang H, Liu Y, Wang Z. Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants. Front Endocrinol (Lausanne) 2020;11:132. [PMID: 32296386 DOI: 10.3389/fendo.2020.00132] [Reference Citation Analysis]
19 Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 2014;8:57. [PMID: 24834023 DOI: 10.3389/fnins.2014.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
20 Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. Mol Pharmacol 2013;83:621-32. [PMID: 23233488 DOI: 10.1124/mol.112.080523] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
21 Kukkonen JP. G-protein inhibition profile of the reported Gq/11 inhibitor UBO-QIC. Biochem Biophys Res Commun 2016;469:101-7. [PMID: 26614908 DOI: 10.1016/j.bbrc.2015.11.078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
22 Morello G, Imperatore R, Palomba L, Finelli C, Labruna G, Pasanisi F, Sacchetti L, Buono L, Piscitelli F, Orlando P, Di Marzo V, Cristino L. Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling. Proc Natl Acad Sci U S A 2016;113:4759-64. [PMID: 27071101 DOI: 10.1073/pnas.1521304113] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
23 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
25 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. IUPHAR BPS Guide Pharm CITE 2021;2021. [PMID: 34927075 DOI: 10.2218/gtopdb/f51/2021.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Putula J, Pihlajamaa T, Kukkonen JP. Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 2014;171:5816-28. [PMID: 25132134 DOI: 10.1111/bph.12883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
27 Berrendero F, Flores Á, Robledo P. When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology 2018;157:43-50. [DOI: 10.1016/j.bcp.2018.08.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
28 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
29 Altinbas B, Guvenc-Bayram G, Yalcin M. The mediation of central cyclooxygenase and lipoxygenase pathways in orexin-induced cardiovascular effects. Brain Res 2021;1754:147239. [PMID: 33412148 DOI: 10.1016/j.brainres.2020.147239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Leino TO, Turku A, Yli-kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EA. Azulene-based compounds for targeting orexin receptors. European Journal of Medicinal Chemistry 2018;157:88-100. [DOI: 10.1016/j.ejmech.2018.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
32 Koesema E, Kodadek T. Global analysis of gene expression mediated by OX1 orexin receptor signaling in a hypothalamic cell line. PLoS One 2017;12:e0188082. [PMID: 29145494 DOI: 10.1371/journal.pone.0188082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Imperatore R, Palomba L, Morello G, Spiezio AD, Piscitelli F, Marzo VD, Cristino L. Formation of OX-1R/CB 1 R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. Pharmacological Research 2016;111:600-9. [DOI: 10.1016/j.phrs.2016.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
34 Turunen PM, Louhivuori LM, Louhivuori V, Kukkonen JP, Åkerman KE. Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell–Cell Contact – Role of mGluR5 and TRPC3 Channels. Neuroscience 2018;375:135-48. [DOI: 10.1016/j.neuroscience.2018.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 Flores A, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci 2013;7:256. [PMID: 24391536 DOI: 10.3389/fnins.2013.00256] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
36 Cristino L, Imperatore R, Di Marzo V. Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. Cannabinoids and Their Receptors. Elsevier; 2017. pp. 61-98. [DOI: 10.1016/bs.mie.2017.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Forte N, Boccella S, Tunisi L, Fernández-Rilo AC, Imperatore R, Iannotti FA, De Risi M, Iannotta M, Piscitelli F, Capasso R, De Girolamo P, De Leonibus E, Maione S, Di Marzo V, Cristino L. Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. Nat Commun 2021;12:6137. [PMID: 34675233 DOI: 10.1038/s41467-021-26388-4] [Reference Citation Analysis]
38 Mohammad-pour Kargar H, Azizi H, Mirnajafi-zadeh J, Ali Reza M, Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Research 2015;1624:424-32. [DOI: 10.1016/j.brainres.2015.07.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
39 Coccurello R, Maccarrone M. Hedonic Eating and the "Delicious Circle": From Lipid-Derived Mediators to Brain Dopamine and Back. Front Neurosci 2018;12:271. [PMID: 29740277 DOI: 10.3389/fnins.2018.00271] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
40 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
41 Toyama S, Shimoyama N, Shimoyama M. The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain. Neuropeptides 2017;61:95-100. [DOI: 10.1016/j.npep.2016.12.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
42 Cristino L, Palomba L, Di Marzo V. New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. Int J Obes Suppl 2014;4:S26-30. [PMID: 27152162 DOI: 10.1038/ijosup.2014.8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
43 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
44 Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF. DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol 2012;8:999-1007. [PMID: 23103940 DOI: 10.1038/nchembio.1105] [Cited by in Crossref: 138] [Cited by in F6Publishing: 136] [Article Influence: 13.8] [Reference Citation Analysis]